Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 28;26(15):7300.
doi: 10.3390/ijms26157300.

Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots

Kate Beecher  1 , Tivya Kulasegaran  1   2 , Sunil R Lakhani  1   3   4 , Amy E McCart Reed  1
Affiliations
Review

Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots

Kate Beecher et al. Int J Mol Sci. .

Abstract

Precision oncology, also known as personalized oncology or precision medicine, is the tailoring of cancer treatment to individual patients based on the specific genetic, molecular, and other unique characteristics of their tumor. The goal of precision oncology is to optimize the effectiveness of cancer treatment while minimizing toxicities and improving patient outcomes. Precision oncology recognizes that cancer is a highly heterogeneous disease and that each patient's tumor has a distinct genetic diversity. Precision medicine individualizes therapy by using information from a patient's tumor in the context of clinical history to determine optimal therapeutic approaches and increasing numbers of drugs target specific tumor alterations. Several targeted therapies with approved companion diagnostics are commercially available, the haves of precision oncology, where predictive biomarkers guide clinical decision-making and improve outcomes. However, many therapies still lack clear biomarkers, the have nots, posing a challenge to fully realizing the promise of precision oncology. Herein, we describe the current state of the art for breast cancer precision oncology and highlight the therapeutic agents that require a more robust biomarker.

Keywords: biomarkers; breast cancer; genomic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The haves and have nots of genomic biomarkers in breast cancer.
See this image and copyright information in PMC

References

    1. WHO Classification of Tumours Editorial Board . Breast Tumours: WHO Classification of Tumours. 5th ed. World Health Organization; Geneva, Switzerland: 2019.
    1. Weigelt B., Geyer F.C., Reis-Filho J.S. Histological types of breast cancer: How special are they? Mol. Oncol. 2010;4:192–208. doi: 10.1016/j.molonc.2010.04.004. - DOI - PMC - PubMed
    1. Sinn H.P., Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care. 2013;8:149–154. doi: 10.1159/000350774. - DOI - PMC - PubMed
    1. Gallagher E.J., Moore H., Lacouture M.E., Dent S.F., Farooki A., Goncalves M.D., Isaacs C., Johnston A., Juric D., Quandt Z., et al. Managing hyperglycemia and rash associated with alpelisib: Expert consensus recommendations using the Delphi technique. npj Breast Cancer. 2024;10:12. doi: 10.1038/s41523-024-00613-x. - DOI - PMC - PubMed
    1. Zehir A., Benayed R., Shah R.H., Syed A., Middha S., Kim H.R., Srinivasan P., Gao J., Chakravarty D., Devlin S.M., et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017;23:703–713. doi: 10.1038/nm.4333. - DOI - PMC - PubMed

Substances

LinkOut - more resources